By
Sequella,
Infectex
Published: March 27, 2017, 1:47 p.m.·
Tags:
Drug-resistant TB,
Treatment
Sequella and Infectex announced positive results of a Phase 2b-3 clinical study of SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary TB (MDR-TB). SQ109 is a new small molecule drug discovered by scientists at Sequella and the US National Institutes of Health.
Read More →
By
Sequella
Published: July 17, 2013, 11:23 p.m.·
Tags:
None
ROCKVILLE, Md. -- Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB).
Read More →